Try Claude
Lead FinderFind & enrich companies and people
AI Tools for Healthcare Consultants
AI tools that help healthcare consultants research clinical evidence, analyze hospital market data, review regulatory requirements, and develop strategy recommendations for health systems and payers.
Get started for free
Works in Chat, Cowork and Code
ACO REACH
597 participating organizations · $1.8B in gross savings generated (2024)
Primary Care First
Expanded to 26 states · prospective payment + performance bonus
AHEAD Model
New in 2025 · states take capitated global budget · 4 states enrolled
Top Implementors
Intermountain · Geisinger · Kaiser — all showing 8–14% cost reduction
Key Challenge
Attribution accuracy and risk adjustment remain top pain points
Clinical evidence synthesis
Pull peer-reviewed research, systematic reviews, and clinical guidelines to support evidence-based strategy recommendations. Replace hours of manual literature review with comprehensive research synthesis.
Find the strongest evidence on telehealth versus in-person care for chronic disease management. Include systematic reviews and randomized controlled trials published in the last 5 years.
Found 12 high-quality studies. Key finding: telehealth equivalent to in-person care for hypertension (BP control, HR 0.98, 95% CI 0.91-1.05) and diabetes management (HbA1c reduction comparable in 8/10 RCTs). Patient satisfaction consistently higher for telehealth (NPS +22 points). Cost savings: 18–35% per encounter in outpatient settings.
ToolRouter search_papers
Studies
12 high-quality studies reviewed · 2020–2025
Hypertension
Telehealth equivalent to in-person (BP control · HR 0.98, CI 0.91–1.05)
Diabetes
HbA1c reduction comparable in 8/10 RCTs
Patient Satisfaction
Consistently higher for telehealth · NPS +22 points
Cost Savings
18–35% per encounter in outpatient settings
Drug and formulary intelligence
Access FDA drug labeling, clinical pharmacology data, and contraindication profiles to support pharmacy benefit management consulting, formulary design, and therapeutic alternative analyses.
Pull FDA label information for tirzepatide (Mounjaro/Zepbound): approved indications, mechanism, dosing schedule, contraindications, boxed warnings, and clinical trial efficacy data.
Retrieved FDA label data. Approved: T2D (Mounjaro) and obesity/overweight (Zepbound). Mechanism: dual GIP/GLP-1 agonist. Dosing: 2.5mg weekly titrating to 15mg. Boxed warning: thyroid C-cell tumors in rodents (unknown human risk). Phase III: 22.5% mean weight loss (SURMOUNT-1). Contraindicated in personal/family history of MTC or MEN2.
ToolRouter get_drug_info
Approved Indications
T2D (Mounjaro) · Obesity/overweight (Zepbound)
Mechanism
Dual GIP/GLP-1 agonist · weekly SC injection 2.5mg → 15mg
Efficacy
22.5% mean weight loss (SURMOUNT-1 Phase III)
Black Box Warning
Thyroid C-cell tumors in rodents · contraindicated in MTC/MEN2 history
Healthcare policy and regulatory research
Research CMS reimbursement changes, HIPAA compliance requirements, state-level Medicaid policies, and accreditation standards. Produce policy briefings that keep health system clients ahead of regulatory shifts.
Research the 2025 CMS Hospital Outpatient Prospective Payment System (OPPS) final rule changes. What are the major reimbursement changes affecting ambulatory surgery centers and what is the projected financial impact?
Key 2025 OPPS changes: (1) 2.9% payment rate update, (2) expanded site-neutral payment policies for off-campus provider-based departments (projected -$1.2B impact on hospital outpatient revenue nationally), (3) new pass-through payment categories for 8 devices. ASC payment rate increase of 3.1%. Recommend modeling impact on your client's specific service line mix.
ToolRouter research
Payment Rate Update
2.9% increase for hospital outpatient services
Site-Neutral Expansion
Off-campus PBDs: projected -$1.2B national impact on hospital OPD revenue
ASC Payment Rate
3.1% increase for ambulatory surgery centers
New Pass-Through
8 new device pass-through payment categories
Recommendation
Model impact on client's specific service line mix
Clinical trial landscape analysis
Search ClinicalTrials.gov to map the pipeline for a therapeutic area, identify competitive trial activity, and research evidence gaps. Support market access strategy and product development consulting.
What Phase II and III trials are currently recruiting for non-alcoholic steatohepatitis (NASH/MASH)? Include sponsor, intervention type, primary endpoints, and expected completion dates.
Found 31 active recruiting trials. 8 in Phase III. Dominant intervention classes: FXR agonists (5 trials), THR-beta agonists (4 trials), combination approaches (6 trials). Resmetirom (Rezdiffra) already approved — competitors target differentiation on fibrosis endpoints. First Phase III readouts expected Q3 2025. Key sponsors: Madrigal, Novo Nordisk, Boehringer Ingelheim.
ToolRouter search_trials
Active Trials
31 recruiting · 8 in Phase III
FXR Agonists
5 trials — dominant class
THR-beta Agonists
4 trials · resmetirom (Rezdiffra) already approved
Key Sponsors
Madrigal · Novo Nordisk · Boehringer Ingelheim
First Phase III Readouts
Expected Q3 2025 · fibrosis endpoints differentiating late entrants
Health system competitive intelligence
Profile competitor health systems, analyze market share shifts, and track service line expansions. Deliver competitive positioning analyses to health system strategy teams preparing for board-level decisions.
Research the competitive positioning of three major health systems in the Denver metro area: UCHealth, SCL Health, and CommonSpirit. Compare service lines, recent expansions, and physician alignment strategies.
Competitive analysis complete. UCHealth leads on academic/research differentiation (CU Anschutz affiliation, 14 COEs). SCL Health strongest in suburban community hospitals (7 facilities). CommonSpirit has broadest geographic coverage but weakest specialty care positioning. Key battleground: orthopedics and cardiovascular service lines.
ToolRouter research_company
UCHealth
Academic/research leader · CU Anschutz affiliation · 14 Centers of Excellence
SCL Health
Strongest suburban community hospital presence · 7 facilities
CommonSpirit
Broadest geographic coverage · weakest specialty care positioning
Key Battleground
Orthopedics and cardiovascular service lines — all three competing
Healthcare business development
Identify strategy, operations, and clinical transformation leaders at health systems, payers, and life sciences companies. Build targeted prospect lists for healthcare consulting business development.
Find Chief Strategy Officers, VP of Business Development, and VP of Clinical Operations at regional health systems (100-500 beds) in the Midwest that have announced value-based care initiatives.
Found 47 contacts at 31 health systems. 18 have value-based care mentions in recent press releases or LinkedIn content. 9 have active strategy or transformation consultant positions posted — indicating budget for external advisory support.
ToolRouter find_leads
NameTitleHealth system
Sarah McKeeChief Strategy OfficerOSF HealthCare
Dr. Chris ParkVP Clinical OperationsAdvocate Aurora
Tamara WellsDir. Care TransformationUnityPoint Health
47 contacts · 31 health systems · 18 with VBC signals
Ready-to-use prompts
Clinical evidence review
Search for systematic reviews and meta-analyses on remote patient monitoring for congestive heart failure published between 2020 and 2025. What is the evidence on readmission reduction, mortality, and cost-effectiveness?
Drug formulary research
Pull FDA prescribing information for the top 5 prescribed diabetes medications: metformin, semaglutide, empagliflozin, sitagliptin, and insulin glargine. For each, include mechanism, indications, key contraindications, and notable drug interactions.
Medicare reimbursement changes
Research the 2025 CMS Physician Fee Schedule final rule. What are the key changes to telehealth reimbursement, evaluation and management codes, and the conversion factor update? Which specialty groups are most affected?
Clinical trial pipeline
Search for Phase II and III trials currently recruiting for Alzheimer's disease. Include sponsor, drug mechanism (amyloid, tau, inflammation), trial size, primary endpoints, and expected readout dates.
Health system competitive analysis
Research the market positioning of HCA Healthcare versus Ascension Health. Compare geographic footprint, service line focus, financial performance, quality metrics, and recent strategic initiatives.
Prospect health system leaders
Find Chief Medical Officers, VP of Population Health, and Director of Care Transformation at academic medical centers and health systems with more than 10,000 employees in the Northeast US.
Value-based care research
Research the current state of accountable care organizations (ACOs) in Medicare. Include number of participating organizations, total savings generated, quality performance trends, and the evolution of Next Generation ACO toward REACH.
Health system profile
Look up [Health System Name] — pull their registered entity details, financial filing data, number of facilities, and any public regulatory or accreditation actions.
Tools to power your best work
Academic ResearchSearch papers, authors, citations
Competitor ResearchDeep intel from a single URL
Content RepurposerTurn any content into posts, scripts, and articles
Deep ResearchAI research reports with citations
Drug InformationDrug info: recalls & side effects
Company LookupCompany data for UK, US & EU
Clinical TrialsClinical trials & drug safety data
165+ tools.
One conversation.
Everything healthcare consultants need from AI, connected to the assistant you already use. No extra apps, no switching tabs.
Healthcare strategy engagement preparation
Before starting a health system engagement, research the regulatory environment, competitive landscape, and clinical evidence base relevant to the strategy question.
Formulary and market access analysis
Analyze drug options for a therapeutic area: evidence base, regulatory status, clinical differentiation, and trial pipeline.
Healthcare business development outreach
Build a prospect pipeline of health system and payer strategy leaders, research their context, and prepare targeted outreach.
Frequently Asked Questions
How current is the FDA drug information?
Drug Information pulls from the FDA DailyMed database, which is updated continuously as manufacturers submit label revisions. The data reflects the most current approved prescribing information. Always cross-reference with the FDA label directly for regulatory submissions.
Can I use academic research results in client deliverables?
Academic Research surfaces peer-reviewed studies from PubMed, Semantic Scholar, and other scholarly databases. The results include citation data and DOIs. Always review the full paper and apply your clinical judgment before including study findings in formal recommendations.
How do I search for trials in a specific geography or patient population?
Clinical Trials searches the ClinicalTrials.gov database and can be filtered by condition, phase, geographic location, age group, and intervention type. Specify your filters in the search prompt for more targeted results.
Can these tools help with health economics and outcomes research?
Academic Research can find HEOR studies, cost-effectiveness analyses, and burden of disease data. Deep Research synthesizes payer coverage policy and reimbursement context. Finance Data provides pharmaceutical and health system financial benchmarks.
How can I research state Medicaid policy differences for a multi-state client?
Deep Research can synthesize state-specific Medicaid managed care policies, formulary requirements, and prior authorization practices. Specify the states and policy domain in your research prompt for a comparative analysis.
Give your AI superpowers.
Get started for free
Works in Chat, Cowork and Code